16 July 2024 - Pharmaceutical giants Johnson & Johnson, BMS and AstraZeneca are rejecting federal district court decisions that rule a government drug price-setting program is constitutional and voluntary.
Opening briefs from Johnson & Johnson and Bristol Myers filed 12 July before the US Court of Appeals for the Third Circuit challenge an April decision from a federal judge in New Jersey that tossed the manufacturers’ claims that the Medicare Drug Price Negotiation Program violates the First Amendment compelled speech doctrine and Fifth Amendment takings clause.